TY - JOUR
T1 - Managing patients on endocrine therapy
T2 - Focus on quality-of-life issues
AU - Whelan, Timothy J.
AU - Pritchard, Kathleen I.
AU - Arteaga, Carlos
AU - Come, Steven
AU - Ingle, James
PY - 2006/2/1
Y1 - 2006/2/1
N2 - Purpose: To review the health-related quality of life (QOL) of women treated with adjuvant hormonal therapy. Experimental Design: To review the limited QOL data from randomized trials of tamoxifen versus placebo and ovarian ablation versus none. To discuss QOL results from randomized trials of aromatase inhibitors compared with tamoxifen or placebo for adjuvant therapy of post-menopausal women with estrogen receptor-positive and/or progesterone receptor-positive breast cancer. Results: QOL is generally good in up to 3 years of follow-up with either tamoxifen or aromatase inhibitors. Vasomotor and sexual complaints remain problematic, however, in only a small proportion of women. There are fewer data regarding the QOL effects of ovarian ablation, which may nonetheless be more substantial. Conclusion: Tamoxifen and aromatase inhibitors cause specific vasomotor or gynecologic symptoms, which may affect sexual function. However, clinical benefits of these agents are generally achieved without major detrimental effect on overall QOL.
AB - Purpose: To review the health-related quality of life (QOL) of women treated with adjuvant hormonal therapy. Experimental Design: To review the limited QOL data from randomized trials of tamoxifen versus placebo and ovarian ablation versus none. To discuss QOL results from randomized trials of aromatase inhibitors compared with tamoxifen or placebo for adjuvant therapy of post-menopausal women with estrogen receptor-positive and/or progesterone receptor-positive breast cancer. Results: QOL is generally good in up to 3 years of follow-up with either tamoxifen or aromatase inhibitors. Vasomotor and sexual complaints remain problematic, however, in only a small proportion of women. There are fewer data regarding the QOL effects of ovarian ablation, which may nonetheless be more substantial. Conclusion: Tamoxifen and aromatase inhibitors cause specific vasomotor or gynecologic symptoms, which may affect sexual function. However, clinical benefits of these agents are generally achieved without major detrimental effect on overall QOL.
UR - http://www.scopus.com/inward/record.url?scp=32944473164&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=32944473164&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-05-2185
DO - 10.1158/1078-0432.CCR-05-2185
M3 - Article
C2 - 16467124
AN - SCOPUS:32944473164
SN - 1078-0432
VL - 12
SP - 1056s-1060s
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 3 II
ER -